Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies

Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies

US Patent 11499154 · Granted Nov 15, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Systemic gene replacement therapy for treatment of X-linked myotubular myopathy 2024
Selective gene therapy expression system2023
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy 2023
Compositions and methods for the treatment of myotonic dystrophy2022
Compositions and methods for the treatment of nucleotide repeat expansion disord2021
Selective gene therapy expression system2018
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy 2018
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy 2017
Systemic gene replacement therapy for treatment of X-linked MyoTubular Myopathy 2016
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy 2015